Videos

Daniel Claassen, MD, MS, shares his approach to diagnosing patients with HD, as well as communicating with patients about the hereditary nature of the disease.

Daniel Claassen, MD, MS, provides an overview of the pathophysiology and genetic background of Huntington’s disease (HD), a neurodegenerative disorder.

The vice president of medical affairs at SK Life Science discussed how epilepsy remains a formidable challenge in the development of effective therapies to achieve seizure freedom. [WATCH TIME: 5 minutes]

The professor of neurology at Johns Hopkins University School of Medicine discussed the traditional view of epilepsy treatment and how the paradigm has shifted to provide new treatments to achieve seizure freedom for drug-resistant patients. [WATCH TIME: 5 minutes]

The professor of neurology in the department of neuroscience at Monash University discussed implementation strategies for treatment approaches to achieve seizure freedom in patients with epilepsy. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]

The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]

Experts discuss the challenges of detecting progression in multiple sclerosis (MS), addressing the lack of available assessment tools but the importance of patient-reported signs and symptoms.

The neurologist at Cleveland Clinic provided perspective on the reasons to study individuals exposed to repetitive head impacts and the lessons learned about monitoring glial fibrillary acidic protein over time. [WATCH TIME: 4 minutes]

Experts begin this series on smouldering multiple sclerosis (MS) highlighting our current understanding of pathophysiology, it’s prevalence, and how we may better detect it in the future.

The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes

Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.

The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]

The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about findings from a real-world study assessing eptinezumab among patients with chronic migraine which was presented at the AHS Scottsdale Headache Symposium 2023. [WATCH TIME: 4 minutes]

The interim chief of pediatric neurology at Stanford Medicine Children’s Health discussed progress in preventing seizures among patients with epilepsy, the potential for gene-targeted therapies, and the importance of localizing where seizures are coming from. [WATCH TIME: 5 minutes]

A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.

Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.

Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.

The director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes]

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]

Neurology experts discuss safety data for BTKIs.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

Ahead of the 2024 MDA Conference, the vice president of public policy and advocacy at the Muscular Dystrophy Association talked about conference advocacy collaboration, access to treatments, and the state of healthcare. [WATCH TIME: 6 minutes]

Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.

The interim chief of pediatric neurology at Stanford Medicine Children’s Health provided insight on advances the screening for epilepsy surgery and the factors that pediatric neurologists should consider. [WATCH TIME: 5 minutes]

The director of the headache section at Cleveland Clinic’s Neurological Institute gave an administrative perspective on the changes to how patients with migraine are cared for, led by significant developments in recent years. [WATCH TIME: 4 minutes]